BioSpace News Archive

Akari Therapeutics, Plc today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle.

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its first quarter 2024 results followed by Q&A on Wednesday, May 1st , 2024, at 8:00 a.m. ET.

Chiesi USA, Inc. today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of April 2024, which is payable on May 15, 2024 to shareholders of record at the close of business on April 30, 2024.

Organovo Holdings, Inc. today released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH).

Celularity Inc. today announced that its expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February for its advanced biomaterial products and biobanking businesses.

Viracta Therapeutics, Inc. today reported positive topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort.

London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and predictable PK parameters.

Viatris Inc. today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company’s Executive Leadership Team, effective today.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31, 2023 and summarized recent business highlights.